Advertisement

Halozyme Therapeutics Inc. said Monday a study showed that that addition of rHuPH20 recombinant human hyaluronidase to three different mealtime insulin analogs accelerated their absorption.

The acceleration of the insulin boosted its effectiveness during the first hour after injection.

The study involved 14 people.

Shares of Halozyme rose 22 cents to close at $7.58.

Advertisement
Advertisement